University of Cambridge > > Cancer Research UK Cambridge Institute (CRUK CI) Seminars in Cancer > TET-family dioxygenases, immune responses and cancer

TET-family dioxygenases, immune responses and cancer

Add to your list(s) Download to your calendar using vCal

  • UserAnjana Rao, La Jolla Institute for Allergy and Immunology World_link
  • ClockThursday 26 September 2019, 13:00-14:00
  • HouseCRUK CI Lecture Theatre.

If you have a question about this talk, please contact Kate Davenport.

In 2009, our lab reported that enzymes of the TET (Ten-Eleven Translocation) family were a new class of epigenetic regulators that altered the modification status of cytosine bases in DNA . The three mammalian TET enzymes – TET1 , TET2 and TET3 – successively oxidize the methyl group of 5-methylcytosine (5mC) to yield 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC) and 5-carboxylcytosine (5caC). These modified cytosine bases (together termed oxidized methylcytosines, oxi-mC) facilitate DNA demethylation and are also novel epigenetic marks. DNA methylation has long been linked to developmental processes and to oncogenesis; similarly TET proteins, which alter DNA modification status, are implicated in numerous biological processes, including cell lineage specification, embryonic development, immune and neuronal function, “stemness” somatic cell reprogramming and cancer. I will discuss the relation between TET activity, DNA modification status and oncogenesis in several model systems with TET loss-of-function.

This talk is part of the Cancer Research UK Cambridge Institute (CRUK CI) Seminars in Cancer series.

Tell a friend about this talk:

This talk is included in these lists:

Note that ex-directory lists are not shown.


© 2006-2024, University of Cambridge. Contact Us | Help and Documentation | Privacy and Publicity